Mechanisms of Osteolytic Bone Destruction

Alsina, Melissa

Abstract

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Cancer Institute (NCI)
• Type: Clinical Investigator Award (CIA) (K08)
• Project #: 1K08CA069136-01A1
• Application #: 2009101
• Study Section: Cancer Research Manpower and Education Review Committee (CRME)
• Project Start: 1996-09-30
• Project End: 2001-09-29
• Budget Start: 1996-09-30
• Budget End: 1997-09-29
• Support Year: 1
• Fiscal Year: 1996

Institution

• Name: University of Texas Health Science Center San Antonio
• Department: Internal Medicine/Medicine
• Type: Schools of Medicine
• DUNS #: 800772162
• City: San Antonio
• State: TX
• Country: United States
• Zip Code: 78229

Publications

Cruz, J C; Alsina, M; Craig, F et al. (2001) Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma. Exp Hematol 29:441-7

Choi, S J; Cruz, J C; Craig, F et al. (2000) Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 96:671-5

Roodman, G D (1997) Mechanisms of bone lesions in multiple myeloma and lymphoma. Cancer 80:1557-63